Macrophage inflammatory protein-1β as a novel therapeutic target for renal protection in diabetic kidney disease.
Chemokine
Diabetic kidney disease
Inflammation
Macrophage inflammatory protein-1β
Podocyte
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
05
01
2023
revised:
15
02
2023
accepted:
23
02
2023
medline:
3
4
2023
pubmed:
3
3
2023
entrez:
2
3
2023
Statut:
ppublish
Résumé
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease worldwide and the prevalence of DKD has increased over recent decades. Inflammation is involved in the development and progression of DKD. In this study, we explored the potential role of macrophage inflammatory protein-1β (MIP-1β) in DKD. Clinical non-diabetic subjects and DKD patients with different levels of urine albumin-to-creatinine ratio (ACR) were enrolled in the study. Lepr
Identifiants
pubmed: 36863097
pii: S0753-3322(23)00238-X
doi: 10.1016/j.biopha.2023.114450
pii:
doi:
Substances chimiques
Ccl4 protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114450Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement The authors declare that there are no conflicts of interest.